Takeo Hara

Takeo Hara

Auto-generated profile, based on publicly available information

Takeo Hara

Division of Gastroenterology, Hepatology, and Nutrition, The Children’s Hospital of Philadelphia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
TKTakashi Kijima
Takashi Kijima
Hiroshi NakagawaHiroshi Nakagawa
Hiroshi Nakagawa
MSMasataka Shimonosono
Masataka Shimonosono
PCPrasanna M. Chandramouleeswaran
Prasanna M. Chandramouleeswaran
THTakeo Hara
Takeo Hara
SNShoji Natsugoe
Shoji Natsugoe
Oropharyngeal and esophageal squamous cell carcinomas, especially the latter, are a lethal disease, featuring intratumoral cancer cell heterogeneity and therapy resistance. To facilitate cancer therapy in personalized medicine, three-dimensional (3D) organoids may be useful for functional characterization of cancer cells ex vivo. We investigated the feasibility and the utility of patient-derived 3D organoids of esophageal and oropharyngeal squamous cell carcinomas. We generated 3D organoids from paired biopsies representing tumors and adjacent normal mucosa from therapy-naïve patients and cell lines. We evaluated growth and structures of 3D organoids treated with 5-fluorouracil ex vivo. Tumor-derived 3D organoids were grown successfully from 15 out of 21 patients (71.4%) and passaged with recapitulation of the histopathology of the original tumors. Successful formation of tumor-derived 3D organoids was associated significantly with poor response to presurgical neoadjuvant chemotherapy or chemoradiation therapy in informative patients (P = 0.0357, progressive and stable diseases, n = 10 vs. partial response, n = 6). The 3D organoid formation capability and 5-fluorouracil resistance were accounted for by cancer cells with high CD44 expression and autophagy, respectively. Such cancer cells were found to be enriched in patient-derived 3D organoids surviving 5-fluorouracil treatment. The single cell-based 3D organoid system may serve as a highly efficient platform to explore cancer therapeutics and therapy resistance mechanisms in conjunction with morphological and functional assays with implications for translation in personalized medicine.

27 February 2020 in Current Protocols in Stem Cell Biology
Verified
Journal Article
Open access
PDF file
HNHiroshi Nakagawa
Hiroshi Nakagawa
YKYuta Kasagi
Yuta Kasagi
TKTatiana A. Karakasheva
Tatiana A. Karakasheva
THTakeo Hara
Takeo Hara
BABailey Aaron
Bailey Aaron
AMAmanda B. Muir
Amanda B. Muir
The homeostatic proliferation‐differentiation gradient in the esophageal epithelium is perturbed under inflammatory disease conditions such as gastroesophageal reflux disease and eosinophilic esophagitis. Herein we describe the protocols for rapid generation (<14 days) and characterization of single‐cell‐derived, three‐dimensional (3D) esophageal organoids from human subjects and mice with normal esophageal mucosa or inflammatory disease conditions. While 3D organoids recapitulate normal epithelial renewal, proliferation, and differentiation, non‐cell autonomous reactive epithelial changes under inflammatory conditions are evaluated in the absence of the inflammatory milieu. Reactive epithelial changes are reconstituted upon exposure to exogenous recombinant cytokines. These changes are modulated pharmacologically or genetically ex vivo. Molecular, structural, and functional changes are characterized by morphology, flow cytometry, biochemistry, and gene expression analyses. Esophageal 3D organoids can be translated for the development of personalized medicine in assessment of individual cytokine sensitivity and molecularly targeted therapeutics in esophagitis patients © 2020 by John Wiley & Sons, Inc.Basic Protocol 1: Generation of esophageal organoids from biopsy or murine esophageal epithelial sheetsBasic Protocol 2: Propagation and cryopreservation of esophageal organoidsBasic Protocol 3: Harvesting of esophageal organoids for RNA isolation, immunohistochemistry, and evaluation of 3D architectureBasic Protocol 4: Modeling of reactive epithelium in esophageal organoids.

28 August 2017 in Diseases of the Esophagus
Verified
Journal Article
Open access
PDF file
KYK. Yamashita
K. Yamashita
TMT. Makino
T. Makino
MYM. Yamasaki
M. Yamasaki
KTK. Tanaka
K. Tanaka
THT. Hara
T. Hara
YDY. Doki
Y. Doki
Although 3-field lymph node dissection (3-FLD) is often performed for thoracic esophageal squamous cell carcinoma (ESCC), the clinical effects of cervical lymph node dissection in addition to mediastinal and abdominal dissections on postoperative complications remain unclear. A total of 367 ESCC patients who underwent curative esophagectomy for thoracic esophageal cancer in our hospital from 2010 to 2015 were included in the study: 157 patients who underwent 2-field lymph node dissection (2-FLD) and 210 patients who underwent 3-FLD. Clinicopathological parameters and postoperative complications based on the Clavien–Dindo classification were compared between the two groups. We performed propensity score matching (PSM) analyses to compare the groups with well-balanced backgrounds. In terms of patient background, clinical T (p < 0.001), N (p < 0.001), and M (p = 0.002) stage of tumor was significantly more advanced; therefore, preoperative treatment was more frequently performed in the 3-FLD group than in the 2-FLD group (91.0% vs. 79.0%, P< 0.001). However, perioperative parameters including operation time, blood loss, and the number of dissected mediastinal and abdominal lymph nodes did not differ between the groups. In terms of postoperative complications, the occurrence rate of pneumonia increased significantly in patients with 3-FLD compared to 2-FLD (grade III or higher: 10.5% vs. 3.2%, P= 0.025). Although the duration of systemic inflammatory response syndrome (SIRS) was longer in the 3-FLD group than in the 2-FLD group (median 3 days vs. 2 days, P= 0.025), other postoperative parameters (including the highest level of postoperative serum C-reactive protein, intensive care unit stay, re-operation rate, and postoperative hospital stay) were similar between the groups. After PSM, the differences in the background between the groups disappeared. PSM analysis showed that there was no significant difference in each complication between the groups. The duration of SIRS tended to be longer in the 3-FLD group than in the 2-FLD group, but the difference was not significant. The field of lymphadenectomy negatively impacted the short-term outcome in ESCC patients in terms of pneumonia and inflammatory response. However, because the results of the PSM analyses indicate that the short-term outcome was similar between the two groups, 3-FLD could be as feasible as 2-FLD in ESCC patients.

4 January 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
THTakeo Hara
Takeo Hara
TMTomoki Makino
Tomoki Makino
MYMakoto Yamasaki
Makoto Yamasaki
KTKoji Tanaka
Koji Tanaka
YMYasuhiro Miyazaki
Yasuhiro Miyazaki
YDYuichiro Doki
Yuichiro Doki

30 March 2017 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
THTakeo Hara
Takeo Hara
YFYoshiyuki Fujiwara
Yoshiyuki Fujiwara
HTHidenori Takahashi
Hidenori Takahashi
KSKeijiro Sugimura
Keijiro Sugimura
JMJeong-Ho Moon
Jeong-Ho Moon
MYMasahiko Yano
Masahiko Yano
Pancreatic neoplasms are usually characterized by ductal, acinar, or endocrine differentiation. Mixed exocrine and endocrine pancreatic tumours are extremely rare. Here, we report a case of pancreatic mixed acinar-endocrine carcinoma (MAEC) with multiple synchronous liver metastases that were treated with surgery and transcatheter arterial chemoembolization (TACE) that later recurred in the stomach. A 45-year-old female with severe anaemia was referred to our hospital. Computed tomography (CT) demonstrated a hypervascular tumour, 17 cm in diameter, that was in the tail of the pancreas. In addition, there were multiple hypervascular tumours in the liver. She underwent a distal pancreatectomy with splenectomy after the liver metastases were treated with TACE. Pathology confirmed that the pancreatic tumour was MAEC. After 4.5 years, a follow-up CT showed a hypervascular tumour at the upper part of the stomach. Gastric endoscopy showed a big tumefactive lesion with surface irregularities, gastric erosion, and multiple dilated vessels in the fornix and greater curvature of the stomach. She underwent a proximal gastrectomy and survived 7 years and 2 months after the start of the treatment. This is the first report of a metastatic stomach tumour from pancreatic MAEC, which was successfully treated with a multidisciplinary approach. Additionally, we review the literature and discuss the treatment of MAEC.

23 April 2020 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
THTakeo Hara
Takeo Hara
TMTomoki Makino
Tomoki Makino
MYMakoto Yamasaki
Makoto Yamasaki
KTKoji Tanaka
Koji Tanaka
KYKotaro Yamashita
Kotaro Yamashita
YDYuichiro Doki
Yuichiro Doki